Comparative Safety and Effectiveness of Heterologous CoronaVac–ChAdOx1 versus Homologous CoronaVac Vaccination in a Real-World Setting: A Retrospective Cohort Study

Comparative Safety and Effectiveness of Heterologous CoronaVac–ChAdOx1 versus Homologous CoronaVac Vaccination in a Real-World Setting: A Retrospective Cohort Study

<b>Background</b>: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has outpaced vaccine availability and delivery from vaccine manufacturers, and thus, a scarcity of vaccines happened to many countries around the world. In Thailand, the mixing of different types...

Full description

Bibliographic Details
Main Authors:	Ayakarn Ruenkham, Suriyon Uitrakul, Peninnah Oberdorfer, Siriporn Okonogi, Wasan Katip
Format:	Article
Language:	English
Published:	MDPI AG 2023-09-01
Series:	Vaccines
Subjects:	heterologous vaccine regimen CoronaVac ChAdOx1 real-world setting homologous vaccine regimen
Online Access:	https://www.mdpi.com/2076-393X/11/9/1458

Similar Items

Intradermal ChAdOx1 Vaccine Following Two CoronaVac Shots: A Case Report
by: Ekachai Singhatiraj, et al.
Published: (2021-09-01)

Placental Transfer Immunity to the Newborns in a Twin Pregnant Women Vaccinated with Heterologous CoronaVac-ChAdOx1
by: Saipin Pongsatha, et al.
Published: (2023-01-01)

Immunogenicity of ChAdOx1 nCoV-19 Booster Vaccination Following Two CoronaVac Shots in Healthcare Workers
by: Wisit Prasithsirikul, et al.
Published: (2022-01-01)

CoronaVac and ChAdOx1 Vaccination and Gamma Infection Elicited Neutralizing Antibodies against the SARS-CoV-2 Delta Variant
by: Marcilio Jorge Fumagalli, et al.
Published: (2022-02-01)

The Effects of CoronaVac and ChAdOx1 nCoV-19 in Reducing Severe Illness in Thailand: A Retrospective Cohort Study
by: Thanyarat Promlek, et al.
Published: (2023-01-01)

Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers
by: Hazal Cansu Çulpan, et al.
Published: (2023-12-01)

The Predictive Value of Gut Microbiota Composition for Sustained Immunogenicity following Two Doses of CoronaVac
by: Ho-Yu Ng, et al.
Published: (2024-02-01)

Immunogenicity of Mix-and-Match CoronaVac/BNT162b2 Regimen versus Homologous CoronaVac/CoronaVac Vaccination: A Single-Blinded, Randomized, Parallel Group Superiority Trial
by: Samar Samoud, et al.
Published: (2023-08-01)

Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study
by: Thiago Cerqueira-Silva, et al.
Published: (2022-02-01)

Humoral and cellular immune responses to CoronaVac up to one year after vaccination
by: Priscilla Ramos Costa, et al.
Published: (2022-10-01)

Immunogenicity after a Third COVID-19 mRNA Booster in Solid Cancer Patients Who Previously Received the Primary Heterologous CoronaVac/ChAdOx1 Vaccine
by: Sutima Luangdilok, et al.
Published: (2022-09-01)

Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines
by: Guy Cohen, et al.
Published: (2022-11-01)

Longitudinal evaluation of innate immune responses to three doses of CoronaVac vaccine
by: Cheng Cao, et al.
Published: (2023-10-01)

Safety Following COVID-19 Booster Vaccine with BNT162b2 Compared to mRNA-1273 in Solid Cancer Patients Previously Vaccinated with ChAdOx1 or CoronaVac
by: Passakorn Wanchaijiraboon, et al.
Published: (2023-02-01)

Humoral Immune Response to CoronaVac in Turkish Adults
by: Yasemin Cosgun, et al.
Published: (2023-01-01)

Prolonged migraine aura resembling ischemic stroke following CoronaVac vaccination: an extended case series
by: Nijasri C. Suwanwela, et al.
Published: (2022-01-01)

Safety and immunogenicity of CoronaVac and ChAdOx1 heterologous prime-boost vaccines in an overweight population in Chiang Mai, Thailand
by: Kriangkrai Chawansuntati, et al.
Published: (2024-06-01)

Humoral anti-SARS-CoV-2 immune response for different strains after Sinovac-CoronaVac and Oxford/AstraZeneca (ChAdOx1-S) full vaccination on a healthcare population in Brazil
by: Maicon Jeferson Silva de Oliveira, et al.
Published: (2024-03-01)

Robust specific RBD responses and neutralizing antibodies after ChAdOx1 nCoV-19 and CoronaVac vaccination in SARS-CoV-2– seropositive individuals
by: Edgar Ruz Fernandes, PhD, et al.
Published: (2023-05-01)

Body Mass Index, Age, and Gender Affect CoronaVac Vaccine Antibody Response
by: Ayfer ÇOLAK, et al.
Published: (2022-08-01)

Safety and immunogenicity of intradermal administration of fractional dose CoronaVac®, ChAdOx1 nCoV-19 and BNT162b2 as primary series vaccination
by: Somruedee Chatsiricharoenkul, et al.
Published: (2022-10-01)

Sobre a eficácia da CoronaVac no Twitter: conversações e aspectos políticos
by: Carina Luisa Ochi Flexor, et al.
Published: (2022-12-01)

Acute prolonged motor aura resembling ischemic stroke after COVID − 19 vaccination (CoronaVac): the first case report
by: Wanakorn Rattanawong, et al.
Published: (2021-08-01)

Metabolomics acts as a powerful tool for comprehensively evaluating vaccines approved under emergency: a CoronaVac retrospective study
by: Xinyu Liu, et al.
Published: (2023-07-01)

Status of Humoral and Cellular Immune Responses within 12 Months following CoronaVac Vaccination against COVID-19
by: Wei Zhao, et al.
Published: (2022-06-01)

Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine
by: Yun Shan Goh, et al.
Published: (2022-01-01)

An Integrative Analysis of the Immune Features of Inactivated SARS-CoV-2 Vaccine (CoronaVac)
by: Zhujun Jiang, et al.
Published: (2022-05-01)

How has research on the effectiveness and safety of COVID-19 vaccination been evaluated: a scope review with emphasis on CoronaVac
by: Juan C. Alzate-Ángel, et al.
Published: (2024-04-01)

Immune Response to CoronaVac and Its Safety in Patients with Type 2 Diabetes Compared with Healthcare Workers
by: Bothamai Dechates, et al.
Published: (2023-03-01)

Comparison of humoral immune response in heterologous and homologous COVID-19 booster vaccine groups using CoronaVac and mRNA-based BNT162b2 vaccines
by: Serkan Atıcı, et al.
Published: (2023-07-01)

Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group
by: Alejandro Escobar, et al.
Published: (2022-01-01)

Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines
by: Ruiqi Zhang, et al.
Published: (2022-04-01)

Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity
by: Daniel Leung, et al.
Published: (2022-09-01)

Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial
by: Mine Durusu Tanriover, et al.
Published: (2022-11-01)

Risk of adverse events following CoronaVac's COVID-19 vaccination in women with and without autoimmunity
by: Stevent Sumantri, et al.
Published: (2023-03-01)

The Early-Term Adverse Effects in Healthcare Personnel after CoronaVac Vaccination
by: Mehmet Kabak, et al.
Published: (2022-03-01)

Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4/5 variants at 3–4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination
by: Suvichada Assawakosri, et al.
Published: (2024-01-01)

Comparison of safety and immunogenicity of CoronaVac and ChAdOx1 against the SARS-CoV-2 circulating variants of concern (Alpha, Delta, Beta) in Thai healthcare workers
by: Nasikarn Angkasekwinai, et al.
Published: (2022-04-01)

Effectiveness of CoronaVac in preventing COVID-19 in healthcare workers
by: Gulsum Iclal Bayhan, et al.
Published: (2022-01-01)

Comparison of antibody responses following natural infection with Severe Acute Respiratory Syndrome Coronavirus 2 or receipt of CoronaVac or ChAdOx1 (AZD1222) vaccination in Chiang Mai, Thailand
by: Sayamon Hongjaisee, et al.
Published: (2023-08-01)